Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral AgentBusiness Wire • 11/14/25
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH TrialBusiness Wire • 11/09/25
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%Investors Business Daily • 11/08/25
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids TrialBusiness Wire • 11/08/25
As Merck Stock Gets Back To Its Feet, Here's One Possible Option TradeInvestors Business Daily • 11/06/25
Merck and Blackstone enter research agreement to develop cancer therapy for $700 millionReuters • 11/04/25
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)Business Wire • 11/04/25
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal AntibodyBusiness Wire • 11/04/25
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.Business Wire • 11/03/25
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock DownZacks Investment Research • 10/30/25
Merck Q3 financial results top estimates, company lowers revenue guidanceProactive Investors • 10/30/25